« Back
Home /
Samotolisib

Samotolisib

Item no.	TMO-T6883-10mM
Manufacturer	TargetMol
CASRN	1386874-06-1
Amount	1 mL x 10 mM (in DMSO)
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mL 1 mg 200 mg 25 mg 2 mg 50 mg 5 mg
Category	Oncology Reagents & Chemicals Molecules By Organ Skin Cancer
Type	Molecules
Specific against	other
Citations	1. Zou Y., Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo. Biochem Biophys Res Commun. 2017 Aug 19;490(2):385-392.
Smiles	COC(C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	GTPL8918,LY3023414
Shipping Condition	Cool pack
Available
Manufacturer - Targets	DNA-PK\|\|\|PI3K\|\|\|Autophagy\|\|\|mTOR
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	406.48
Description	Samotolisib (LY3023414) is an oral ATP competitive inhibitor of the class I PI3K isoforms, DNA-PK, and mTOR. Samotolisib (LY3023414) has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.
Pathways	DNA Damage/DNA Repair\|\|\|PI3K/Akt/mTOR signaling\|\|\|Autophagy
Bioactivity	LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK.
Receptor	DNA-PK; mTOR kinase; class I PI3K isoforms

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T6883-10mM-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mL x 10 mM (in DMSO)

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question